Active	Status	Sponsor type	Region	Phase	Filter
5 Active 2 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kim, Hyosong
MP-VAC-206, NCT06219733: Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)	Withdrawn	2	76	RoW	Vactosertib, Imatinib	MedPacto, Inc.	Dermoid	05/22	05/22
Hwang, Sunjin
MP-VAC-206, NCT06219733: Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)	Withdrawn	2	76	RoW	Vactosertib, Imatinib	MedPacto, Inc.	Dermoid	05/22	05/22
KEYNOTE 900, NCT03724851: Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer	Active, not recruiting	1/2	120	RoW	TEW-7197, vactosertib	MedPacto, Inc., Merck Sharp & Dohme LLC	Metastatic Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	05/24	01/25
NCT03698825: TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer	Completed	1/2	62	RoW	TEW-7197, vactosertib	MedPacto, Inc.	Metastatic Gastric Cancer	01/22	12/22
MP-VAC-203, NCT03732274: Phase 1b/2a, Open-label Study of Vactosertib in Combination with Durvalumab in Advanced NSCLC	Active, not recruiting	1/2	60	RoW	TEW-7197, vactosetib	MedPacto, Inc., AstraZeneca	Non-Small Cell Lung Cancer Metastatic	05/24	12/24